MiNK Therapeutics, Inc. (INKT)
Nasdaq · Healthcare · Biotechnology
$12.20−1.93%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $62.3M
- 52-week range
- $8.48 – $16.93
- 52-week change
- −16.51%
- EPS (trailing)
- −$2.39
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$12.5M
- Diluted EPS
- −$2.93
From the company’s annual report on SEC EDGAR.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Headquarters: New York, United States · 15 employees · minktherapeutics.com